The spectrum of breast lesions, including atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), lobular carcinoma in situ (LCIS) and flat epithelial atypia (FEA), represents a ... ascopubs.org: Evaluation of the Tyrer-Cuzick (International Breast Cancer Intervention Study) Model for Breast Cancer Risk Prediction in Women With Atypical Hyperplasia Accurate breast cancer risk assessment is vital to personalize screening and risk reduction strategies. Women with atypical hyperplasia have a four-fold higher risk of breast cancer.
We evaluated the ... Evaluation of the Tyrer-Cuzick (International Breast Cancer Intervention Study) Model for Breast Cancer Risk Prediction in Women With Atypical Hyperplasia ascopubs.org: Model for Predicting Breast Cancer Risk in Women With Atypical Hyperplasia Women with atypical hyperplasia (AH) on breast biopsy have an aggregate increased risk of breast cancer (BC), but existing risk prediction models do not provide accurate individualized estimates of ... Breast lesions encompass an array of benign and pre-malignant conditions with significant implications for patient management and cancer prevention. Among these, atypical ductal hyperplasia (ADH) is a ...
atypical hyperplasia, Atypical endometrial hyperplasia (AEH) occurs when the lining of the uterus is too thick and contains abnormal cells. It can cause vaginal bleeding and may progress to cause further symptoms. AEH is a ... ascopubs.org: Assessment of the Accuracy of the Gail Model in Women With Atypical Hyperplasia An accurate estimate of a woman's breast cancer risk is essential for optimal patient counseling and management. Women with biopsy-confirmed atypical hyperplasia of the breast (atypia) are at high ...
atypical hyperplasia, Assessment of the Accuracy of the Gail Model in Women With Atypical Hyperplasia ascopubs.org: A phase II study of medroxyprogesterone acetate plus metformin as fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. A phase II study of medroxyprogesterone acetate plus metformin as fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer.
